US Stock MarketDetailed Quotes

HALO Halozyme Therapeutics

Watchlist
  • 47.790
  • -1.210-2.47%
Close Nov 25 16:00 ET
  • 47.910
  • +0.120+0.25%
Post 17:39 ET
6.08BMarket Cap15.82P/E (TTM)

Halozyme Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Halozyme Therapeutics Q3 2024 Earnings Date

Currency：USDOct 31, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
252.17M
290.08M
+37.92M
Beat Est.
+16.73%
+34.28%
+15.04%
EPS
0.83
1.05
+0.22
Beat Est.
+35.59%
+72.13%
+26.95%
Analyst Rating
Buy

Nov 25, 2024

Halozyme Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
Date Period Revenue/Estimate Earnings Call
-- 2025/Q1 -- / 257.678M --
-- 2024/Q4 -- / 292.097M --
Oct 31, 2024 2024/Q3 290.084M / 252.167M --
Aug 6, 2024 2024/Q2 231.353M / 204.941M --
May 7, 2024 2024/Q1 195.879M / 199.649M --
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 257.678M--
--2024/Q4-- / 292.097M--
Oct 31, 20242024/Q3290.084M / 252.167M--
Aug 6, 20242024/Q2231.353M / 204.941M--
May 7, 20242024/Q1195.879M / 199.649M--

Unlock Free Earnings Estimates

Halozyme Therapeutics Earnings Reports

  • Halozyme Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 1 10:32

  • Halozyme Therapeutics | 8-K: HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

    Nov 1 04:12

  • Halozyme Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 7 04:43

  • Halozyme Therapeutics | 8-K: HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS

    Aug 7 04:07

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 25, 2024

    Buy

    • Buy

      50.00%

    • Hold

      50.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data